吡咯-1-羧酸氯化物 | 92776-70-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯
• 中文名称: 吡咯-1-羧酸氯化物
• 英文名称: pyrrole-1-carboxylic acid chloride
• 英文别名: N-Pyrrolecarboxylic acid chloride；1H-pyrrole-1-carbonyl chloride；1-Pyrrolcarbonsaeurechlorid；pyrrole-1-carbonyl chloride；Pyrrol-1-carbonylchlorid
• CAS: 92776-70-0
• 化学式: C₅H₄ClNO
• 分子量: 129.546
• InChiKey: HWEBOXZPJDFLEO-UHFFFAOYSA-N

物化性质

• 沸点：
  211.4±23.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  22
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  吡咯-1-羧酸氯化物 在 RhCl(PPh₃)3 吡啶 、 rhodium(II) hexanoate 、 氢气 作用下， 以 四氢呋喃 、 乙醇 、 正己烷 为溶剂， 反应 24.0h， 生成 Methyl 8-((2-(trimethylsilyl)ethoxy)carbonyl)-8-azabicyclo<3.2.1>oct-2-ene-2-carboxylate
  参考文献：
  名称：

  Synthesis of (.+-.)-ferruginine and (.+-.)-anhydroecgonine methyl-ester by a tandem cyclopropanation/Cope rearrangement

  摘要：

  Rhodium(II) acetate catalyzed decomposition of vinyldiazomethanes in the presence of N-(alkoxycarbonyl)pyrroles led to the synthesis of 8-azabicyclo[3.2.1]octa-2,6-dienes. The vinylcarbenoids generated from vinyldiazomethanes with a single electron-withdrawing group exhibited competing reactivity at the vinyl terminus in addition to the carbenoid site. Good regiocontrol was possible, however, by appropriate choice of catalyst and solvent. The practicality of this new approach to tropane alkaloids was demonstrated through short syntheses of (+/-)-ferruginine, (+/-)-anhydroecgonine methyl ester, and the lower homologue of (+/-)-anatoxin a.

  DOI：

  10.1021/jo00019a044
• 作为产物：
  描述：

  乙基吡咯-1-羧酸酯 在 氢氧化钾 、 氯仿 、 五氯化磷 作用下， 生成 吡咯-1-羧酸氯化物
  参考文献：
  名称：

  Tschelinzew; Maxorow, Chemische Berichte, 1927, vol. 60, p. 196

  摘要：

  DOI：

文献信息

• CAJANINE STRUCTURE ANALOGOUS COMPOUND, PREPARATION METHOD AND USE
  申请人：INSTITUTE OF MEDICINAL BIOTECHNOLOGY. CHINESE ACADEMY OF MEDICAL SCIENCES

  公开号：US20140371232A1

  公开（公告）日：2014-12-18

  Provided are cajanine structure analogous compounds, synthesis method and pharmacological effects thereof, the compounds of the present invention having the structure as represented by general formulas I, II, III, IV and V. Also provided are pharmaceutical compositions containing the compounds as active ingredient, and uses thereof; the compounds of the present invention having the pharmacological activities such as anti-virus, anti-virus-infection, nerve protection, anti-metabolic-diseases and the like. Also provided is a chemical total synthesis preparation method of the natural products cajanine, cajanine A and cajanine C. The present invention lays a foundation for the in-depth study and development of the compounds as clinical drugs in the future.

  提供的是与咖啡碱结构类似的化合物、合成方法及其药理效果，本发明的化合物具有如公式I、II、III、IV和V所代表的结构。还提供了含有这些化合物的药物组合物，以及它们的使用方法；本发明的化合物具有诸如抗病毒、抗病毒感染、神经保护、抗代谢性疾病等药理活性。还提供了天然产物咖啡碱、咖啡碱A和咖啡碱C的化学全合成制备方法。本发明为这些化合物作为未来临床药物深入研究和发展奠定了基础。
• [EN] HETEROARYL DERIVATIVES AS PARP INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROARYLE UTILISÉS EN TANT QU'INHIBITEURS DE PARP
  申请人：LUPIN LTD

  公开号：WO2017029601A1

  公开（公告）日：2017-02-23

  Disclosed are compounds of formula (I), their tautomeric forms, stereoisomers, and pharmaceutically acceptable salts thereof, wherein ring Ar, ring B, R1-R5, X, Y, p, q, r, and s are as defined in the specification, pharmaceutical compositions including a compound, tautomer, stereoisomer, or salt thereof, and methods of treating or preventing diseases or disorders, for example, cancer, that are amenable to treatment or prevention by inhibiting the PARP enzyme of a subject.

  公开的是式(I)的化合物，其互变异构体、立体异构体和药学上可接受的盐，其中环Ar、环B、R1-R5、X、Y、p、q、r和s的定义如规范中所述，包括一种化合物、互变异构体、立体异构体或其盐的药物组合物，以及治疗或预防疾病或紊乱的方法，例如癌症，通过抑制受试者的PARP酶可治疗或预防的疾病或紊乱。
• Total synthesis of prodigiosin
  作者：Dale L. Boger、Mona Patel

  DOI：10.1016/s0040-4039(00)95451-0

  日期：1987.1

  The total synthesis of prodigiosin (1), possessing the characteristic pyrrolylpyrromethene skeleton of a class of naturally-occurring polypyrroles, is detailed, The approach is based on the application of an inverse electron demand Diels-Alder reaction of dimethyl 1,2,4,5-tetrazine-3,6-dicarboxylate in a 1,2,4,5-teirazine → 1,2-diazine → pyrrole strategy for preparation of prodigiosin pyrrole ring

  详细介绍了具有一类天然存在的聚吡咯的特征吡咯基吡咯亚甲基骨架的prodigiosin（1）的全合成，该方法基于二甲基1,2,4的反电子需量Diels-Alder反应的应用， 1,2,4,5-替拉嗪中的5-四嗪-3,6-二羧酸→1,2-二嗪→吡咯策略，用于制备pro原苷吡咯环B，并随后实施分子内钯（II）促进2 ，2'-二芳基（2,2'-联吡咯）偶联用于构建prodigiosin 2,2'-联吡咯AB环系统。
• Amine derivative compounds
  申请人：SANKYO COMPANY, LIMITED

  公开号：US20030078426A1

  公开（公告）日：2003-04-24

  An amine compound of the formula (I): 1 wherein R 1 represents an optionally substituted carbamoyl group, etc., R 2 represents a hydrogen atom, etc., R 3 represents a C 1 -C 10 alkyl group etc., W 1 , W 2 and W 3 are the same or different and each represent a single bond or a C 1 -C 8 alkylene group, X, Y and Q represent a sulfur atom, etc., Z represents a ═CH— group, etc., Ar represents a benzene ring, etc. and L represents a hydrogen atom, etc., or a pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc.

  化合物的结构式（I）如下：其中R1代表可选择取代的氨基甲酰基团，R2代表氢原子等，R3代表C1-C10烷基等，W1、W2和W3相同或不同，每个代表单键或C1-C8烷基链，X、Y和Q代表硫原子等，Z代表═CH—基团等，Ar代表苯环等，L代表氢原子等，或其药理学上可接受的盐。这些化合物在治疗和/或预防糖尿病、高脂血症、动脉硬化、癌症等疾病方面具有用处。
• [EN] PYROLLIDINE-BASED COMPOUNDS<br/>[FR] COMPOSÉS À BASE DE PYROLLIDINE
  申请人：SHANGHAI TARGETDRUG CO LTD

  公开号：WO2009092293A1

  公开（公告）日：2009-07-30

  A compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof, which can inhibit HIV replication.

  一种化合物，其化学式为（I），或其药学上可接受的衍生物、盐或前药，能够抑制HIV的复制。